Enabling the immune system to fight cancer

With support from Bristol-Myers Squibb and Ultimovacs, UV1 will be tested in a large, randomized combination trial in mesothelioma initiated by Oslo University Hospital.

Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.

Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.